
-
Atara Biotherapeutics NasdaqGS:ATRA Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Location: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320, United States | Website: https://www.atarabio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
53.64M
Cash
13.84M
Avg Qtr Burn
-16.81M
Short % of Float
12.22%
Insider Ownership
19.53%
Institutional Own.
40.13%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EBVALLO (tabelecleucel) (Tab-cel) Details Viral infection, Epstein-Barr virus, Nasopharyngeal carcinoma, Solid organ transplant, Hematopoietic cell transplantation | BLA Resubmission | |
ATA3219 Details Systemic lupus erythematosus, Lupus nephritis, Autoimmune disease | Phase 1 Update | |
ATA3219 Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1 Update | |
ATA188 Details Multiple sclerosis, Epstein-Barr virus | Failed Discontinued |